MedTrace Logo

The Appropriate Level of Continuous Adductor Canal Block in Patients Undergoing Total Knee Arthroplasty (TKA)

NCT04206150 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2021-10-15

No results posted yet for this study

Summary

Adductor canal catheters are being used to provide continuous postoperative analgesia after total knee arthroplasty surgery (TKA). There is much debate about where is the best position of continuous adductor canal block in patients undergoing TKA. Therefore, the investigators aim to compare the postoperative pain at three different level of continuous adductor canal block. Ninety six patients scheduled for total knee arthroplasty will be randomly divided into the three groups. In group 1, the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal). In group 2, the adductor canal catheter is inserted femur length/15\*2 cm above the location where the nerve block performed in group 1. In group 3, the adductor canal catheter is inserted femur length/15cm below the location where the nerve block performed in group 1.

Conditions

  • Degenerative Arthritis

Interventions

PROCEDURE

the three different sites of continous adductor canal block: the adductor canal catheter is inserted at femoral triangle apex

In group 1, the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal).

PROCEDURE

the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15*2 cm above the location

In group 2, the adductor canal catheter is inserted femur length/15\*2 cm above the location where the nerve block performed in group 1.

PROCEDURE

the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15 cm below the location

In group 3, the adductor canal catheter is inserted femur length/15 cm below the location where the nerve block performed in group 1.

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-02
Primary Completion
2021-07-16
Completion
2021-07-17

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04206150 on ClinicalTrials.gov